AstraZeneca : FDA Accepts For Review SBLA For Self-administration Of Flumist Quadrivalent

(RTTNews) - AstraZeneca PLC (AZN.L, AZN) said that its Supplemental Biologics License Application or sBLA for the approval of a self- or caregiver-administered option for Flumist Quadrivalent (Influenza Vaccine Live, Intranasal), a needle-free nasal spray, has been accepted for r https://www.nasdaq.com/articles/astrazeneca-:-fda-accepts-for-review-sbla-for-self-administration-of-flumist-quadrivalent